Advaxis Skyrockets on Resumed Clinical Trials
Advaxis has announced that the FDA has lifted the clinical hold on all of its Investigational New Drug (IND) applications for its three product candidates
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Advaxis Inc. (NASDAQ: ADXS) was absolutely running away early in Wednesday’s regular session on the release of an U.S. Food and Drug Administration (FDA) restriction. The company announced that the FDA has lifted the clinical hold on all of the company’s Investigational New Drug (IND) applications for its three product candidates: axalimogene filolisbac, ADXS-PSA and ADXS-HER2.
As a result, the company will resume all clinical trials for the aforementioned candidates.
Advaxis received notification from the FDA in October that its IND applications for axalimogene filolisbac were put on clinical hold in response to the company’s submission of a safety report to the FDA. The clinical hold also included the INDs for ADXS-PSA and ADXS-HER2.
Following discussions with the FDA and in accordance with their recommendations, Advaxis agreed to implement certain risk-mitigation measures, including revised study protocol inclusion/exclusion criteria, post-administration antibiotic treatment and patient surveillance and monitoring measures.
Daniel J. O’Connor, president and CEO of Advaxis, commented:
We appreciate the FDA’s review of this matter. We are grateful that our clinical trials will now resume so that we may continue investigating new treatments for unmet medical needs. We thank both the patients and their physicians for their participation in our clinical trials.
Advaxis has outperformed the market so far in 2015, with its shares up over 3%. Over the past 52 weeks, the stock is up roughly 90%.
Shares of Advaxis were trading up more than 33% at $11.11, with a consensus analyst price target of $29.50 and a 52-week trading range of $4.37 to $30.13.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
